Usefulness of lipid-lowering therapy in elderly patients

American Journal of Cardiology

Volumn 90, Issue 8, 2002, Pages 870-871

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ELDERLY CARE; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SCREENING; SHORT SURVEY; STROKE;

EID: 0037108120     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02710-8     Document Type: Note

References (10)

1. Denke M.A., Grundy S.M. Hypercholesterolemia in elderly persons resolving the treatment dilemma . Ann Intern Med. 112:1990;780-792.
2. Wilson PWF, Kannel WB. Hyper-cholesterolemia and coronary risk in the elderly: the Framingham Study. Am J Geriatr Cardiol 1993;2:52-56.
3. Lemaitre R.N., Furberg C.D., Newman A.B., Hulley S.B., Gordon D.J., Gottdiener J.S., McDonald R.H. Jr, Psaty B.M. Time trends in the use of cholesterol-lowering agents in older adults the Cardiovascular Health Study . Arch Intern Med. 158:1998;1761-1768.
4. Miettinen T.A., Pyörälä K., Olsson A.G., Musliner T.A., Cook T.J., Faergeman O., Berg K., Pedersen T., Kjekshus J., Scandinavian Simvastatin Study Group . Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 96:1997;4211-4218.
5. Lewis S.J., Moye L.A., Sacks F.M., Johnstone D.E., Timmis G., Mitchell J., Limacher M., Kell S., Glasser S.P., Grant J., Davis B.R., Pfeffer M.A., Braunwald E., CARE Investigators . Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range results of the Cholesterol And Recurrent Events (CARE) trial . Ann Intern Med. 129:1998;681-689.
6. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1348-1357.
7. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
8. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.